Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4086940 for Weight Management in Adults With Obesity or Overweight
NCT07890376Phase 2Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2026
- Primary completion
- Jan 2028
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of LY4086940 in obesity (10 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Body Weight at 32 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
LY4086940
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07890376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890376.